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Despite multimodal treatment, it is not possible to cure
high-grade glioma (HGG) patients. Therefore, the aim
of treatment is not only to prolong life, but also to
prevent deterioration of health-related quality of life as
much as possible. When the patient’s condition declines
and no further tumor treatment seems realistic, patients
in the Netherlands are often referred to a primary care
physician for end-of-life care. This end-of-life phase
has not been studied adequately yet. The purpose of
this study was to explore specific problems and needs
experienced in the end-of-life phase of patients with
HGG. We retrospectively examined the files of 55
patients who received treatment in our outpatient
clinic and died between January 2005 and August
2008. The clinical nurse specialist in neuro-oncology
maintained contact on a regular basis with (relatives
of) HGG patients once tumor treatment for recurrence
was no longer given. She systematically asked for signs
and symptoms. The majority of the patients experienced
loss of consciousness and difficulty with swallowing,
often arising in the week before death. Seizures occurred
in nearly half of the patients in the end-of-life phase and
more specifically in one-third of the patients in the week
before dying. Other common symptoms reported in the
end-of-life phase are progressive neurological deficits,
incontinence, progressive cognitive deficits, and head-
ache. Our study demonstrates that HGG patients,
unlike the general cancer population, have specific symp-
toms in the end-of-life phase. Further research is needed
in order to develop specific palliative care guidelines for
these patients.
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P
atients with high-grade glioma (HGG), the most
frequently occurring primary malignant brain
tumor, have a poor prognosis and cannot be
cured. Despite aggressive multimodality treatment with
surgery, radiation therapy, and chemotherapy, median
survival ranges from ,1 to 5 years depending on histo-
logical subtype, tumor grade, cytogenetic analysis, age,
and performance status at the time of diagnosis.1,2
Focal neurological deficits, symptoms of increased
intracranial pressure, epilepsy, and cognitive dysfunc-
tion are prominent symptoms in HGG patients which
may arise in any stage of the disease.3–5 Furthermore,
fatigue, mood disturbances, and anxiety are often
reported.6 These factors all negatively affect
health-related quality of life (HRQOL) of patients and
their relatives.7–9 Antitumor treatment as well as sup-
portive medication [often steroids and antiepileptic
drugs (AEDs)] may cause side effects which may
further diminish HRQOL.10,11 Since HGG patients
cannot be cured, the aim of treatment is not only to
prolong life, but also to maintain quality of life as long
as possible. In this respect, HRQOL is included as a sec-
ondary endpoint in a growing number of randomized
clinical trials evaluating antitumor treatment.12,13
When the patient’s condition declines due to tumor
progression and further tumor treatment is not an
option, the end-of-life phase begins. In this phase, only
supportive treatment is given.14 In the Netherlands,
patients in this phase often no longer visit the
neuro-oncology outpatient department and become
dependent on care provided by primary care physicians.
Depending on where the patient resides, the general
practitioner, the nursing home specialist, or the
hospice doctor is the coordinating physician. In the
Netherlands, only a minority of cancer patients dies in
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hospitals, which probably also holds true for HGG
patients.15,16
Patients and their relatives often are anxious about
what will happen in the last phase of life.
Until now, there are limited data on the end-of-life
phase of these patients.4,17–19 The few existing reports
identified symptoms related to increased intracranial
pressure (headache and drowsiness), as well as progress-
ive neurological deficits, epileptic seizures, confusion/
delirium, fatigue, and dysphagia as the most prominent
symptoms.17–19
A better knowledge of the clinical issues for this
specific group of patients in the end-of-life phase will
improve the information given to future HGG patients
and their families as well as the care supplied. We there-
fore explored the incidence of specific symptoms in the
end-of-life phase in a group of HGG patients.
Patients and Methods
Patients
Adult (.18 years of age) glioma patients, who had died
between January 2005 and August 2008 after being
treated for their tumor at the VU University Medical
Centre, Amsterdam, were considered for inclusion in
the analysis.
Patients with either an initial histological diagnosis of
HGG (glioblastoma multiforme, high-grade astrocy-
toma, high-grade oligodendroglioma, or high-grade
mixed glioma) or a histological confirmed low-grade
glioma (LGG), with clinical and radiological progression
suspected for a high-grade tumor following initial treat-
ment, were included. According to our definition, the
end-of-life phase started once patients presented with
progressive disease for which there were no further
tumor treatment options, or if patients refused further
tumor treatment. Patients who died during tumor treat-
ment were therefore excluded.
Materials and Methods
In the end-of-life phase, patients no longer visited the
outpatient clinic on a regular basis. The clinical nurse
specialist, however, kept in touch with the patients
and/or their families via a telephone service. Patients
and caregivers were invited to call the clinical nurse
specialist in the case of questions and problems.
Otherwise, the clinical nurse specialist contacted the
patients and/or their main informal caregiver(s) on a
biweekly basis and asked for signs, symptoms, and pro-
blems encountered. In these telephone contacts, using a
checklist, the clinical nurse specialist investigated the
occurrence of pain, headache, focal neurological deficits,
confusion, cognitive disturbances, seizures, and inconti-
nence, as well as the level of consciousness, changes in
medication (antiepileptics and steroids), and problems
with intake of medication, fluid, and food (Fig. 1).
Furthermore, in the month following death, the
course of the disease in the last week before dying was
enquired after with the family or the primary care
physician.
Symptoms, signs, and treatment in the end-of-life
phase as a whole were retrieved from medical files and
the chart of the clinical neuro-oncology nurse specialist.
Symptoms and problems arising in the week before
death were recorded separately.
Statistical Analysis
We used SPSS software 15.0 for statistical analysis.
Results
Demographic and Clinical Data
Seventy-five consecutive adult HGG patients, who ended
all tumor treatment while being treated at our centre,
and died between January 2005 and August 2008,
were identified. Seventeen (relatives of) patients did not
use the telephone service. Nine of these 17 were referred
to another institution in the end-of-life phase and had a
contact person there. The other 8 declined the service.
Fifty-eight patients were included in this analysis. Of
these 58 patients, 12 patients had been diagnosed with
an LGG before dedifferentiation to an HGG.
Table 1 shows demographic and clinical data.
Symptoms and Signs in the End-of-Life Phase
Three of the 58 cases were lost to follow-up in the
end-of-life phase and therefore excluded. Two of these
patients died in a nursing home, and 1 passed away
at home. In Table 2, symptoms and signs occurring
anytime in the end-of-life phase are depicted.
The most frequently reported symptom was
decreased consciousness (87% of the patients) which,
however, was not reported until the last week before
death in the majority of patients (73% of these patients).
The second most common symptom was dysphagia.
This occurred in 71% of the cases and often coincided
with decreased consciousness. Fifty-two percent of the
patients experienced progressive neurological deficits
Fig. 1. Checklist used in the telephone interviews.
Sizoo et al.: End of life in high-grade glioma patients
NEURO-ONCOLOGY † N O V E M B E R 2 0 1 0 1163
 at Vrije Universiteit Amsterdam on July 11, 2011
n
e
u
ro
-o
n
cology.oxfordjournals.org
D
ow
nloaded from
 
(motor deficit, coordination loss, and/or aphasia).
Seizures were reported in 45% of all patients in the
end-of-life phase. Of patients who already had seizures
during the course of disease, 53% also had seizures in
the end-of-life phase. Conversely, of patients who had
been free of seizures so far, 11% had their first seizure
in the end-of-life phase. Thirteen (52%) of the 25
patients who had seizures in the end-of-life phase had
more than 1 seizure in this phase. All patients with sei-
zures received AEDs. Among the patients who were on
anticonvulsive drugs, there were no patients who never
had epileptic seizures. In 40% of the patients, inconti-
nence was reported to occur before the patients were
bed-ridden. Headache, progressive cognitive deficits
(memory loss, personality changes, apathy, and
problems in executive functioning and understanding),
and agitation/confusion all were reported in one-third
of the patients. Next to headache, 25% of the patients
reported bodily pain, often related to immobilization.
Additionally Reported Symptoms
In addition to the symptoms and signs structurally asked
for, other symptoms and signs which were additionally
reported by the patients and their caregivers are given
in Table 3. Twenty-five percent of the patients experi-
enced severe fatigue and 20% of the patients suffered
from nausea or vomiting. Dyspnea was reported in 9
patients (16%): in 5 cases, this was most likely due to
pneumonia, in 1 patient due to pulmonary embolism,
whereas in the remaining 3 cases, the cause of dyspnea
was unclear. Constipation, probably due to morphine
use, was severe enough to be reported in 5 cases. In
5 patients, symptoms of anxiety and/or depression
were mentioned. One patient had severe vertigo due to
tumor infiltration in the 8th cranial nerve. Severe side
effects from steroid use were reported in 4 cases: 2
patients suffered from steroid myopathy, 1 patient devel-
oped hyperglycemia, and 1 patient had a bowel perfor-
ation while using steroids. Overall, 44 (80%) patients
used steroids in the end-of-life phase.
Symptoms in the Week Before Dying
Although drowsiness was only present in 13 patients
(24%) at the start of the week before dying, this
number increased to 48 patients (87%) during the last
week. This also holds true for dysphagia: the number
increased from 5 patients (9%) to 39 patients (71%).
In the last week, 28% of all patients experienced at
least 1 seizure.
Cause of Death
In 40 patients (73%), the presumed cause of death was
brain herniation due to tumor progression. For 4 other
patients, the cause of death was directly tumor-related;
these patients died following a seizure (3 patients) or a
hemorrhage in the tumor (1 patient). For 8 patients,
the cause of death was indirectly tumor-related; 5
patients died due to an infection (in 2 cases, this con-
cerned an aspiration pneumonia following a seizure), 1
died from bowel perforation while using steroids, 1
patient died from pulmonary embolism, and 1 suffered
Table 1. Demographic and clinical data (n ¼ 58)
Sex
Male 39 (67%)a
Female 19 (33%)a
Age at diagnosis (y) 52 (18–81)b
Grade
Grade III 15 (26%)a
Grade IV 41 (71%)a
Unspecifiedc 2 (3%)a
History of LGG 12 (21%)a
Survivald in months
Grade III 21 (11–86)b
Grade IV 12 (0.5–71)b
Length of the end of life phase, days 46 (1–294)b
Place of death
† At home 38 (66%)a
† Hospital 10 (17%)a
† Hospice 5 (8.5%)a
† Nursing home 5 (8.5%)a
Abbreviation: LGG, low-grade glioma.
aNumber of patients (%).
bMedian (range).
cClinically and radiological evidenced.
dFrom diagnosis.
Table 2. Symptoms documented anytime in the end-of-life
phase (n ¼ 55)
Symptoms Number of
patients (%)
Drowsiness/progressive loss of consciousness 48 (87)
Dysphagia 39 (71)
Progressive focal neurological deficits (motor,
dysphasia)
28 (51)
Seizures 25 (45)
Incontinencea 22 (40)
Progressive cognitive deficits 18 (33)
Headache 18 (33)
Confusion 16 (29)
Bodily pain 14 (25)
aBefore the patient was confined to bed.
Table 3. Additionally reported symptoms (n ¼ 55)
Symptoms Number of patients (%)
Fatigue 14 (25)
Nausea/vomiting 11 (20)
Dyspnea 9 (16)
Constipation 5 (9)
Anxiety/depressive symptoms 5 (9)
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traumatic brain damage following an accident and died
from urosepsis. In 3 patients, euthanasia was performed
under strict conditions upon a voluntary and well-
considered request.
Discussion
The most commonly reported symptoms in the last
phase of our cohort of HGG patients were drowsiness
(87%), dysphagia (71%), progressive neurological defi-
cits (51%), seizures (45%), incontinence (40%), pro-
gressive cognitive deficits (33%), and headaches
(33%). Of these, drowsiness and dysphagia appeared
to occur most frequently in the week before death.
One of the drawbacks of this study is the focus on
symptoms specific for brain tumors. The more general
end-of-life symptoms reported in extracranial cancer
patients, such as fatigue, mood disturbances, nausea,
and constipation, are probably underreported as these
were not structurally asked for.20,21 Another restraint
is the relatively small number of patients. Despite these
limitations, our data are worth reporting, given the
lack of studies in this field.
In 3 earlier studies in patients dying from brain
tumors, comparable prevalence rates of increased intra-
cranial pressure symptoms (drowsiness and headache),
neurological deficits, seizures, and cognitive deficits
were reported.17–19 The occurrence of dysphagia,
however, differed among these studies. Dysphagia was
reported in 70% of our cases, more or less comparable
to the studies by Oberndorfer et al.17 and Pace et al.18
In contrast, Faithfull et al.19 described a prevalence of
only 10%. This discrepancy in prevalence rates is prob-
ably due to the fact that we also denominated patients to
be dysphagic if they were unable to swallow due to loss
of consciousness. If these patients are excluded, only
14% had (true) dysphagia.
The high prevalence of swallowing difficulties in the
last week of life may yield problems in taking medi-
cation. The majority of patients used AEDs and/or glu-
cocorticoids (dexamethasone) in the last phase of life.
About one-third of the patients suffered from seizures
in the last week of life and these may be life-threatening
as appeared to be the case in 5 patients. Since seizures are
even a more prominent feature in the end-of-life phase
than we had anticipated, continuation of AEDs should
therefore be recommended, even if oral administration
is no longer possible. In view of the fact that most
patients stay at home or in a first-line care setting, a non-
invasive administration route is preferred when patients
are unable to swallow at the end of life. Rectal adminis-
tration of carbamazepine, valproic acid, and phenobar-
bital is available. Otherwise, seizures may be treated
with rectal diazepam, intranasal or subcutaneous mida-
zolam or sublingual clonazepam.22 In the hospital
setting, intravenous infusion should be considered.
Urinary incontinence has not been described in
former reports concerning the end-of-life phase of
brain tumor patients. In our cohort, it was a relatively
early and prominent sign (before the patient was con-
fined to bed) occurring in 41% of the cases.
Incontinence has often been associated with immobiliz-
ation, social withdrawal, body image distortion, and
depression and thus has a major impact on quality of
life.23 Urinary incontinence, specifically in brain tumor
patients, can be caused by the tumor itself, such as
may be the case in frontal tumors, or due to impaired
cognition and consciousness. Other (reversible) causes
may be urinary tract infection, hyperglycemia, and the
use of sedatives.23 In a general cancer population, 29%
of the patients were incontinent for urine in the
end-of-life phase.24 Thus, the prevalence of incontinence
appears to be relatively high in brain tumor patients.
Of further interest is to compare the prevalence of
more “general” end-of-life symptoms in HGG patients
with other cancer patients. The main symptoms reported
in terminally ill cancer patients are fatigue and anorexia,
followed by pain, nausea, constipation, delirium, and
dyspnea.20,21 As noted before, these symptoms are prob-
ably underreported in our patients, since we did not ask
for general symptoms. However, bodily pain was asked
for and appeared to occur less frequently in glioma
patients (25%) when compared with patients with sys-
temic cancer, where prevalence rates of 60%–80% are
reported.24 Despite the fact that we are still unaware
of the prevalence of general symptoms in glioma patients
in the end-of-life phase, the disease-specific symptoms
are prominent. This indicates that the end-of-life phase
of HGG patients cannot be compared simply with a
general cancer population. Future studies prospectively
exploring the end-of-life phase of HGG patients are
mandatory in order to develop specific palliative care
guidelines for these patients and their relatives.
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